(A) Journal Articles

1. Liu YM, 2020, Understanding profit margins of medical providers from prescription drugs: Evidence from Taiwan. International Health. DOI: 10.1093/inthealth/ihz072.
2. Liu YM, 2020, 再論藥價差, 台灣公共衛生雜誌. 39(1), 64-73.
3. Liu YM, 2020, Population Aging, Technological Innovation, and the Growth of Health Expenditure: Evidence from Patients with Type 2 Diabetes in Taiwan. Value in Health Regional Issues. 21(C): 120-126.
4. Chang YC, Yen MF, Chang SM, Liu YM, 2017, Exploring the relationship between nursing hours per patient day and mortality rate of hospitalized patients in Taiwan. Journal of Nursing Management, 25, 85-92.
5. Ou HT, Chang KC, Liu YM, Wu JS, 2017, Recent trends in utilization of antidiabetic medications from 2008-2013: a nation-wide population-based study from Taiwan. Journal of Diabetes, 9, 256-266.
6. Liu YM, Lo TF, Nien YT, 2017, 醫院退出市場因素之分析. 台灣公共衛生雜誌. 36(3), 273-287.
7. Ou HT, Chen YT, Liu YM, Wu JS, 2016, “Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan”, Diabetes Research and Clinical Practice, 116, 14-25.
8. Liu, Ya-Ming, Huang-Tz Ou, and Yen-Kuang Yang, 2014 “Choice of Generic versus Brand-Name Antidepressants in a Regulated Prescription Drug Market: Evidence from Taiwan”, The Journal of Mental Health Policy and Economics, 17(4), 163-172. (SSCI)
9. Liu, Ya-Ming and Chee-Ruey Hsieh, 2014, “Profit-Seeking Behavior of Medical Providers and Generic Competition in the Pharmaceutical Market: Evidence from Taiwan”, The B.E. Journal of Economic Analysis & Policy, 14(1), 241-275. (SSCI)
10. 李妙純，劉亞明（2013年05月）。台灣中高齡人口不同世代所得相關死亡率不平等之年齡變化趨勢。台灣公共衛生雜誌，32(3), 279-288。（TSSCI）
11. Chee-Ruey Hsieh, Ya-Ming Liu, Chia-Lin Chang (2013, Apr). Endogenous Technological Change in Medicine and Its Impact on Health Care Costs: Evidence from the Pharmaceutical Market in Taiwan.European Journal of Health Economics, 14(2), 287-295. (SSCI).
12. Hsieh, Chee-Ruey and Ya-Ming Liu. 2012. “Availability, Healthcare Costs and Utilization Patterns of Biologics in Taiwan.” Value in Health. 15(1), S35-S42. (SSCI)
13. Liu, Ya-Ming, and Jur-Shan Cheng, 2012, “Determinants of generic entry in the regulated Taiwanese prescription drug market”, Health Policy. 108(2-3), 228-235. (SSCI)
14. Liu, Ya-Ming and Chee-Ruey Hsieh, 2012, “New Drugs and the Growth of Health Expenditure: Evidence from Diabetic Patients in Taiwan”, Health Economics. 21(5), 496-513.(SSCI)
15. Liu, Ya-Ming, Yea-Huei Kao Yang, and Chee-Ruey Hsieh, 2012, “Regulation and Competition in the Taiwanese Pharmaceutical Market under National Health Insurance”, Journal of Health Economics. 31(3), 471-483.(SSCI)
16. Liu, YM, YH Kao Yang, and CR Hsieh, 2011, "The Determinants of the Adoption of Pharmaceutical Innovation: Evidence from Taiwan", Social Science &Medicine. Forthcoming (SSCI)
17. Liu, YM, 2010, “Exploring the Income Effect from Health Insurance: Evidence from in Taiwan”, Empirical Economics Letters. 9(8) (EconLit)
18. Liu, YM, YH Kao Yang, and HZ Ou, 2010, “Hospital Competition and Prescribing Behaviors –Empirical Evidence from Taiwan”, Journal of Developing Areas. 43(2), 125-141. (EconLit)
19. Liu, YM, YH Kao Yang, and CR Hsieh, 2009, “Financial Incentives and Physicians' Prescription Decisions on the Choice between Brand-Name and Generic Drugs: Evidence from Taiwan”, Journal of Health Economics. 28(2), 341-349. (SSCI, EconLit).
20. Chang, HH and Liu, YM, 2009, “The Impact of Brand Equity on Brand Preference and Purchase Intentions in the Service Industries,” Service Industries Journal. 29(12): 1687-1706. (SSCI)
21. 劉亞明,高雅慧, 張瓊云, 2008, “健保新藥的使用與高血壓患者醫療支出的關係：以「血管張力素受體阻斷剤」為例.” 健康保險期刊, 4(2), 31-47.
22. Liu, YM, 2007, “Hospital Competition under Global Budgets: Evidence from Diabetes Outpatient Treatments in Taiwan,” The Empirical Economics Letters, 6(1), 46-52. (EconLit)
23. Liu, YM and J Kinsey, 2005, “The Effect of Competition on the Practice of Outpatient Services for Diabetes Patients at Different Levels of Hospitals in Taiwan,” Applied Economics,37(12), 1411-1422. (SSCI, EconLit)
24. Liu, YM, 2004, “An Application of Adverse Selection: Rural Agricultural Production in China since the 1950s,” Applied Economics Letters, 11, 915-917. (SSCI, EconLit)
25. 劉亞明，「大陸鄉鎮企業的產權結構分析」，《中國大陸研究》，第40卷第8期 (1997年8月)，頁71-81。(TSSCI)

(B) Conference Papers

1. Liu, YM and TW Wang, July 2015, “An Application of the Growth Model of Endogenous Technological Change in Health Care”, WEAI 90th Annual Conference, Hawaii, USA.
2. Hsieh, CR, TF Lo, and YM Liu, June 2014, “Access to the Public Home Health Care and the Use of Health Care Services among the Elderly: Are They Substitutes or Complements?” 5th Biennial Conference of the American Society of Health Economists, Los Angeles, USA.
3. Liu, YM and CR Hsieh, July 2013, “National Health Insurance and Profit-Seeking Behavior in the Prescription Drug Market: Evidence from Taiwan.” iHEA 9th World Congress, Sydney, Australia.
4. Liu, YM, and CR Hsieh, Sept. 2010, "New Drugs and the Growth of Health Expenditure: Evidence from Diabetic Patients in Taiwan", ISPOR 4th Asia-Pacific Conference, Sept.5-7, 2010, Phuket, Thailand.
5. 何志欽、廖肇寧、劉亞明、蔡群立，八八水災災後重建預算配置效率之影響評估—區域可計算一般均衡模型之應用，可計算一般均衡模型在產業發展評估之應用研討會,國立成功大學社會科學院, 2010年11月10日
6. Liu, YM, YH Kao Yang, and CR Hsieh, December 2009, “Market Competition and the Adoption of Pharmaceutical Innovation: Evidence from Taiwan,” 2009 Annual Meeting of Taiwan Society of Health Economics, Taipei, Taiwan.
7. Liu, YM, YH Kao Yang, and CR Hsieh, September 2009, “Regulation and Competition in the Pharmaceutical Market under National Health Insurance,” 2009 Health Services Research Summer Conference, Taipei, Taiwan.
8. Liu, YM, July 2009, “Exploring the Income Effect from National Health Insurance: Evidence from the Variation of Household Expenditures in Taiwan”, Oral presentation at the International Health Economics Association 6th World Congress, July 12-15, 2009, Beijing, China.
9. Liu, YM, YH Kao Yang, and CY Chang, Sept 2008, “Utilization of new drug and medical expenditure of hypertension patients: empirical evidence from angiotensin II receptor blockers in Taiwan” Oral presentation at the ISPOR 3rd Asia-Pacific Conference, Sept.7-9, 2008, Seoul, South Korea.
10. Liu,YM, YH Kao Yang, and CR, Hsieh, November 2008, “Financial Incentives and Physicians' Prescription Decisions on the Choice between Brand-Name and Generic Drugs: Evidence from Taiwan”, Oral presentation at the Provider Payment Incentives in the Asia-Pacific Conference, November 7-8, 2008, Beijing, China.
11. Liu, YM, YH Kao Yang, and PC Chen, “Reimbursement Price of Pharmaceuticals and Brand Name - Generic Drugs Utilization: Evidence from Oral Hypoglycemic Agents for Ambulatory Care in Taiwan”, the International Health Economics Association 6th World Congress, July 7-11, 2007 Copenhagen, Denmark.
12. YH Kao Yang, YM Liu, PC Chen and PY Yeh Liu, November 2006, “The Impacts of the National Health Insurance Reimbursement Price on the Utilization of Oral Hypoglycemic Agents for Ambulatory Care”, 21st Congress of Federation of Asian Pharmaceutical Association, Yokohama, Japan. (NSC95-2415-H-006-006)
13. Liu, YM, June 2006, “Hospital Competition under Global Budgets: Evidence from Diabetes Outpatient Treatments in Taiwan”, 2006 Annual Research Meeting of Academy for Health Services Research and Health Policy, June 25-27, 2006, Seattle, USA. (NSC94-2415-H-006-003)
14. Liu, Ya-Ming, Huang-Zi Ou and Yea-Huei Kao Yang, November 2005, “Hospital Nonprice Competition and Drug Utilization: A Case Study of Outpatient Services for Diabetes Mellitus in Taiwan”, American Public Health Association's 133rd Annual Meeting, Dec 10-14, 2005, Philadelphia, PA, USA.
15. 劉亞明與陳治達，「不同層級醫院非價格競爭行為之實證分析－以糖尿病患為例」，第六屆全國實證經濟學論文研討會，台灣，高雄，2005年5月。
16. Liu, Ya-Ming, “An Extension of Hospital Nonprice Competition Model: A Case Study of Outpatient Services for Diabetes Patients”, 2003 Annual Meeting of Taiwan Economic Association, Taipei.